Core Viewpoint - UBS has raised the target price for Gu Ming (01364.HK) to HKD 31.15 while maintaining a "Buy" rating, citing strong same-store sales growth and an aggressive store opening plan as key factors for the positive outlook [1] Group 1: Company Performance - Gu Ming has achieved approximately 10% same-store sales growth this year, exceeding UBS's previous estimates [1] - The company's store opening plan is set to reach between 1,500 to 2,000 locations, which is also better than prior expectations [1] - The strong performance is attributed to product innovation and subsidies from JD.com in food delivery [1] Group 2: Valuation and Forecast - UBS has increased its earnings forecast for Gu Ming, projecting it to be 4% to 14% higher than market peers [1] - The target price adjustment from HKD 19.28 to HKD 31.15 is based on a discounted cash flow (DCF) valuation method [1] - The new target price corresponds to forecasted price-to-earnings ratios of 34 times and 27 times for 2025 and 2026, respectively, with a dynamic P/E ratio of 1.4 times for 2025, which is lower than the average P/E ratios of 43 times and 35 times for new consumption peers [1]

青侨阳光医药投资 - 交流探讨 港股医药过去几年经历了 20 年一遇的大跌，但这倒过来说，一旦企稳，这可能是 20 年一遇的机遇。虽然医药后 周期，但市场迟早会发现医药行业 " 总量稳健增长 + 创新持续爆发 " 蕴含的大量优质成长和潜在双击。 下面是 12 月 7 日在深圳雪球嘉年华和小丰总一起探讨的视频。 变局之下，医药行业的投资机会 视频来源于雪球 app 的 @ 雪球嘉年华。 以下为我们在这次交流过程中涉及到的对当下医药行业不同角度的探讨~ 1 最初选择聚焦医药时， 医药行业最吸引人的地方是什么？ 我们认为医药最吸引人的地方： 当然，这种结构性的搅动，看对了是机遇，看错了就是挑战了。所以， 医药 行业还是很好的，商业模式不 错，增长速度快，增量机会也多，但 对"看对方向、选对股票"的要求比较高 。 2 医药作为整体投资逻辑还是挺有吸引力的， 为什么过去几年医药股的股价还落后了这么多？ 我们的理解，至少也有3个原因： 对产业来说，前沿技术路线越多越好，说明创新活跃，机会很多。 但对投资者来说，方向太多根本跟踪不过来，而且也容易挑花眼。 不过只是后周期的话也不必太担心。至少行业基本面很健康，后面可能慢慢也 ...